

Press Release

Abliva AB (publ), 556595-6538
23 June 2020 10:45:00 CEST - Lund,
Sweden



Abliva – Virtual Capital Markets Day today at 3.00 p.m.

Abliva AB (Nasdaq Stockholm: ABLI) – today, 23 June 2020, holds a virtual Capital Markets Day. The theme of the day will be the company's new strategic focus on primary mitochondrial disease, the most important pharmaceutical projects and the market potential.

Program (approximate time):

3:00 p.m. Introduction CEO Erik Kinnman.

3:10 p.m. Medical need and the science CMO Magnus Hansson.

3:25 p.m. Development activities Director Clinical and Regulatory Affairs, Matilda Hugerth.

3:35 p.m. Interview with CEO Erik Kinnman.

3:45 p.m. Interview with Roger Franklin, partner Hadean Ventures, new owner and board member.

3:50 p.m. Questions and Answers from analysts and received via ir@abliva.com.

Approx. 4:30 p.m. Conclusions.

The Capital Markets Day is moderated by Charlotte Stjerngren, Cord Communications. The presentation material will be in English, but the lectures will mainly be held in Swedish.

The Capital Markets Day can be followed via Abliva's website at: <http://abliva.com/sv/investor/capital-markets-day-2020/>. The recording will also be posted afterwards.

Questions can be asked to ir@abliva.com.

For more information, please contact:

Catharina Johansson, CFO, IR & Communications
+46 (0)46-275 62 21, ir@abliva.com

Abliva AB (publ)

Medicon Village, SE-223 81 Lund, Sweden
Tel: +46 (0)46 275 62 20 (switchboard)
info@abliva.com, www.abliva.com

For news subscription, please visit: <http://abliva.com/press-releases/subscription-page/>

Follow us on LinkedIn: <https://www.linkedin.com/company/abliva>

Subscribe to our YouTube channel: <https://www.youtube.com/channel/UCChqP7Ky5caXtp72CELhD6Mg>

Abliva AB (publ) - the mitochondrial medicine company. The company is listed on Nasdaq Stockholm, Small Cap, under the ticker symbol ABLI.

Press Release

Abliva AB (publ), 556595-6538
23 June 2020 10:45:00 CEST - Lund,
Sweden



About Us

Abliva AB is a leader in mitochondrial medicine, with one project in clinical phase I (KL1333) for chronic treatment of primary mitochondrial diseases and one project, in preparation for clinical trials (NV354), for treatment of primary mitochondrial diseases with Complex I deficiency. NeuroSTAT for traumatic brain injury (TBI) is ready to enter a clinical phase II efficacy study. The R&D portfolio also consists of early projects. Abliva's ambition is to take drugs for primary mitochondrial diseases through clinical development and all the way to market, with or without partners. For the TBI and NASH projects the goal is to enter strategic partnerships. A subset of compounds under the NVP015 program has been licenced to Fortify Therapeutics, a BridgeBio company, for local treatment development of Leber's Hereditary Optic Neuropathy (LHON). Abliva is listed on Nasdaq Stockholm, Sweden (ticker: ABLI).

Attachments

[Abliva – Virtual Capital Markets Day today at 3.00 p.m.](#)